Merck & Co. (MRK)
(Delayed Data from NYSE)
$127.00 USD
+0.12 (0.09%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $127.02 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
MRK 127.00 +0.12(0.09%)
Will MRK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MRK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRK
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
4 Large Drug Stocks to Hold on to Amid Industry Challenges
MRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Other News for MRK
Merck & Co raises annual outlook thanks to first quarter boost
Merck KGaA lays cornerstone for research centre in Darmstadt
Merck: Q1 Earnings Snapshot
Merck Announces First-Quarter 2024 Financial Results
Merck raises guidance as Keytruda sales jump 20% in Q1